FDA's monitoring of postmarketing studies probed

被引：0

|

作者：

Young, Donna

机构：

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2006年 / 63卷 / 16期

关键词：

D O I：

10.2146/news060003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

收藏

页码：1485 / 1486

页数：2

相关论文

共 50 条

[41] Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
Zeitoun, Jean-David
Ross, Joseph S.
Atal, Ignacio
Vivot, Alexandre
Downing, Nicholas S.
Baron, Gabriel
Ravaud, Philippe
[J]. BMJ OPEN, 2017, 7 (12):
[42] A postmarketing safety programme for generic ticlopidine is being considered by the US FDA
[J]. Reactions Weekly, 1999, 753 (1) : 2 - 2
[43] REVIEW OF COMPANY POSTMARKETING SURVEILLANCE STUDIES
WALLER, PC
WOOD, SM
LANGMAN, MJS
BRECKENRIDGE, AM
RAWLINS, MD
[J]. BRITISH MEDICAL JOURNAL, 1992, 304 (6840): : 1470 - 1472
[44] THE CONTRIBUTION OF SPONTANEOUS MONITORING TO POSTMARKETING SURVEILLANCE OF MEDICINES
MEYBOOM, RHB
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (05) : 1639 - 1639
[45] Supporting pharmaceutical studies for FDA submissions: diversifying the drug monitoring laboratory
Moyer, TP
Oliver, LK
[J]. CLINICAL CHEMISTRY, 1998, 44 (02) : 433 - 436
[46] US FDA's safety monitoring of drugs with expedited approval
Furlow, Bryant
[J]. LANCET ONCOLOGY, 2016, 17 (03): : 281 - 281
[47] POSTMARKETING SURVEILLANCE - AVOID PROMOTIONAL STUDIES
INMAN, WHW
[J]. BRITISH MEDICAL JOURNAL, 1994, 309 (6954): : 608 - 609
[48] Mandatory postmarketing paediatric studies in the USA
[J]. Reactions Weekly, 2018, 1731 (1) : 6 - 6
[49] The US FDA is to review postmarketing reports of serious bleeding associated with dabigatran etexilate
[J]. Reactions Weekly, 2011, 1382 (1) : 5 - 5
[50] Concerns about status of postmarketing studies
[J]. Reactions Weekly, 2013, 1462 (1) : 5 - 5

← 1 2 3 4 5 →